Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRS1220, a selective and potent antagonist for the human A3 adenosine receptor (hA3AR) with a dissociation constant (Ki) of 0.59 nM, exhibits therapeutic promise for central nervous system disease research. It effectively diminishes glioblastoma tumor size and inhibits blood vessel formation in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 197.00 | |
10 mg | In stock | $ 313.00 | |
25 mg | In stock | $ 533.00 | |
50 mg | In stock | $ 768.00 | |
100 mg | In stock | $ 1,080.00 | |
500 mg | In stock | $ 2,160.00 |
Description | MRS1220, a selective and potent antagonist for the human A3 adenosine receptor (hA3AR) with a dissociation constant (Ki) of 0.59 nM, exhibits therapeutic promise for central nervous system disease research. It effectively diminishes glioblastoma tumor size and inhibits blood vessel formation in vivo. |
In vitro | MRS 1220 reverses the effect of A3 agonist-elicited inhibition of tumor necrosis factor-α formation in the human macrophage U-937 cell line with an IC50 of 0.3 μM[1]. VEGF secretion in U87MG glioblastoma stem-like cells (GSCs) decreases ~25% with MRS1220 after 72 h of hypoxia[2]. |
In vivo | MRS1220 (0.15 mg/kg; intraperitoneal inoculation) reduces tumor size and blood vessel formation in vivo. MRS1220 exhibits a strong in vivo anti-angiogenic effect[2]. |
Synonyms | MRS 1220 |
Molecular Weight | 403.82 |
Formula | C21H14ClN5O2 |
CAS No. | 183721-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7.2mg/mL (17.8mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MRS1220 183721-15-5 GPCR/G Protein Neuroscience Adenosine Receptor MRS-1220 MRS 1220 inhibitor inhibit